We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NICE Recommends Janssen’s Olysio for Hepatitis C

NICE Recommends Janssen’s Olysio for Hepatitis C

September 24, 2014

The UK’s health-cost watchdog has recommended coverage of Janssen hepatitis C drug Olysio, but also has asked for more data proving its effectiveness in certain patient populations.

In a preliminary guidance, the National Institute for Health and Care Excellence (NICE) this week recommended the drug be funded in combination with peginterferon alfa and ribavirin for patients with genotype 1 hepatitis C. NICE is holding off on genotype 4, however, until Janssen can prove that the drug is effective in that patient population.

Olysio (simeprevir) received European marketing authorization in conjunction with other medicines for patients with genotypes 1 and 4 hepatitis C, with or without cirrhosis, and in patients who also have HIV.

In its submission to the UK, Janssen told the agency that the UK’s genotype 4 population is very small and that data from genotype 1 patients could automatically be applied to those with genotype 4. The appraisal committee found this assertion “highly uncertain,” and asked NICE to request that Janssen provide evidence of the natural history of genotype 4 and its response to drug treatment as compared with genotype 1.

NICE also said it has doubts about the drug’s effectiveness for either genotype when combined with Gilead Sciences’ Sovaldi (sofosbuvir), with or without ribavirin. Janssen supported this indication with an open-label, single-arm trial with too few patients, none of whom had genotype 4, the appraisal committee said.

Janssen plans to continue discussing clinical data for genotype 4 and for the sofosbuvir combination with NICE, spokesman Hans Vanavermaete said. — Lena Freund

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Drugs Submissions and Approvals

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 07Dec

      Proactive Supplier Management Using Quality Agreements

    • 13Dec

      FDA Inspection Overhaul: How Things Have Changed in 2023

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Biden Offers Drug Supply Chain Fixes, but Think Tank Says Government Isn’t Doing Enough

    • FDA Gives Green Light to Medtronic’s Symplicity Renal Denervation System

    • T-cell Malignancy From CAR-T Cell Immunotherapies Gets FDA Investigation

    • Vivos Sleep Apnea Oral Device Gets FDA Nod While Philips Wrestles With Yet Another CPAP Safety Issue

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing